Clinical Trials Logo

HER-2 Gene Amplification clinical trials

View clinical trials related to HER-2 Gene Amplification.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03783936 Completed - Clinical trials for Gastric Adenocarcinoma

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Start date: January 24, 2019
Phase: Phase 2
Study type: Interventional

The initial intent of the study was to be a multi-center single-arm open-label Simon's two-stage Phase II clinical trial of first-line mFOLFOX6 + trastuzumab + avelumab in metastatic HER2-amplified gastric and esophageal adenocarcinomas. Accrual will halt after completion of Stage I (enrollment of 18 patients). This decision is not due to safety issues. Subjects currently on treatment will continue until criteria as defined in the protocol is met.

NCT ID: NCT03613168 Completed - Cholangiocarcinoma Clinical Trials

Trastuzumab in HER2-positive Biliary Tract Cancer

BILHER
Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of current standard gemcitabine plus cisplatin.

NCT ID: NCT03602079 Completed - Prostate Cancer Clinical Trials

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Start date: July 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

NCT ID: NCT01304784 Completed - Clinical trials for HER-2 Gene Amplification

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.